Alzheimer's experts call on FDA to pull Biogen's Aduhelm
Alzheimer’s disease researchers along with medical professors from Harvard and Johns Hopkins issued a formal statement Monday asking the FDA to quickly pull Biogen’s Aduhelm from the market.
“An accelerated withdrawal would mitigate some of the harm of its unwarranted accelerated approval,” they wrote to FDA, explaining how Aduhelm “did not meet the FDA’s own criteria for accelerated approval based on surrogate markers because amyloid plaque does not correlate well with symptoms, severity of disease or progression.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.